Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals (REGN) is a US-based biotechnology company known for developing monoclonal antibody therapies and using human genetics to inform drug discovery. Its leading marketed products include EYLEA for retinal disease and Dupixent (co‑developed with Sanofi) for certain inflammatory conditions — both are material revenue drivers. The firm combines laboratory platforms (VelocImmune) and the Regeneron Genetics Center to identify and advance targets across ophthalmology, immunology, oncology and rare diseases. Investors should note Regeneron’s strengths in proprietary discovery technology and a deep pipeline, balanced by typical sector risks: R&D intensity, regulatory approval uncertainty, patent and pricing pressures, and possible revenue concentration around key drugs. With a market capitalisation near $61.4bn, the stock can be volatile around trial, approval and commercial updates. This summary is educational and not financial advice; consider your risk tolerance and consult a financial adviser to determine suitability.
Why It's Moving
Regeneron rallies 5% as FDA expands Eylea HD label, reigniting hopes for its blockbuster revival.
Shares of Regeneron surged over 5% after the FDA approved an expanded label for Eylea HD, allowing use in macular edema from retinal vein occlusion with dosing up to eight weeks—the first such interval for this condition. This move sidesteps biosimilar pricing pressure while boosting patient convenience, signaling a strategic turnaround for the biotech giant's core ophthalmology franchise after a two-year slump.
- FDA's recent label expansion for Eylea HD introduces longer dosing intervals, enhancing competitiveness and stabilizing Regeneron's flagship revenue stream amid biosimilar threats.
- Pipeline gains momentum with Lynozyfic approval for multiple myeloma, positive late-stage data for cemdisiran in myasthenia gravis, and new ventures into GLP-1 muscle preservation therapies.
- Company bolsters shareholder returns via a new $0.88 quarterly dividend paid December 5th and active buyback program, underscoring confidence in its diversified growth path.
Regeneron rallies 5% as FDA expands Eylea HD label, reigniting hopes for its blockbuster revival.
Shares of Regeneron surged over 5% after the FDA approved an expanded label for Eylea HD, allowing use in macular edema from retinal vein occlusion with dosing up to eight weeks—the first such interval for this condition. This move sidesteps biosimilar pricing pressure while boosting patient convenience, signaling a strategic turnaround for the biotech giant's core ophthalmology franchise after a two-year slump.
- FDA's recent label expansion for Eylea HD introduces longer dosing intervals, enhancing competitiveness and stabilizing Regeneron's flagship revenue stream amid biosimilar threats.
- Pipeline gains momentum with Lynozyfic approval for multiple myeloma, positive late-stage data for cemdisiran in myasthenia gravis, and new ventures into GLP-1 muscle preservation therapies.
- Company bolsters shareholder returns via a new $0.88 quarterly dividend paid December 5th and active buyback program, underscoring confidence in its diversified growth path.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Regeneron's stock, predicting it could rise to $785.9.
Financial Health
Regeneron Pharmaceuticals is performing exceptionally well with strong profits, revenue growth, and cash flow.
Dividend
Regeneron Pharmaceuticals offers a low dividend yield of 0.36%, which may not attract income-focused investors. If you invested $1000, you would be paid $3.60 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring REGN
Obesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: September 10, 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: August 3, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Strong product drivers
EYLEA and Dupixent are significant revenue sources and shape near-term cashflow, though sales can be sensitive to competition and reimbursement changes.
Genetics-driven R&D
Regeneron’s genetics and VelocImmune platforms can accelerate target discovery and bespoke antibodies, offering scientific optionality while R&D outcomes remain uncertain.
Regulatory sensitivity
Product approvals, label changes and pricing decisions across markets materially affect valuation; investors should expect updates to move the share price.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
